Shopping Cart
- Remove All
- Your shopping cart is currently empty
XRK3F2 is an inhibitor of the p62-ZZ domain, blunts MM-induced Runx2 suppression in vitro, and induces new bone formation and remodeling in the presence of tumor in vivo.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $34 | In Stock | |
5 mg | $79 | In Stock | |
10 mg | $122 | In Stock | |
25 mg | $236 | In Stock | |
50 mg | $372 | In Stock | |
100 mg | $559 | In Stock | |
1 mL x 10 mM (in DMSO) | $89 | In Stock |
Description | XRK3F2 is an inhibitor of the p62-ZZ domain, blunts MM-induced Runx2 suppression in vitro, and induces new bone formation and remodeling in the presence of tumor in vivo. |
In vitro | XRK3F2 inhibits p62-ZZ domain signaling and rescues Myeloma-induced Gfi1-driven epigenetic repression of the Runx2 gene in pre-osteoblasts to overcome differentiation suppression. XRK3F2 prevents MM-induced upregulation of Gfi1 and repression of the Runx2 gene when present in MM-preOB co-cultures. p62-ZZ-domain blocking by XRK3F2 prevents MM conditioned media and TNF plus IL7-mediated Gfi1 mRNA upregulation and the concomitant Runx2 repression. XRK3F2 decreased MM-induced GFI1 occupancy at the Runx2-P1 promoter and prevented recruitment of HDAC1, thus preserving the transcriptionally permissive chromatin mark H3K9ac on Runx2 and allowing osteogenic differentiation[1]. |
Molecular Weight | 435.89 |
Formula | C23H24ClF2NO3 |
Cas No. | 2375193-43-2 |
Smiles | Cl.OCCNCc1ccc(OCc2ccc(F)cc2)c(OCc2ccc(F)cc2)c1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 135.0 mg/mL (309.7 mM), Sonication is recommended. H2O: 0.8 mg/mL (1.9 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.